Shilpa Medicare Limited
Related Stocks
About
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Price Range
52 Week
Low
259.50
High
825.40
Intraday
Low
807.80
High
823.00
Company's profit divided by outstanding shares.
Ratio of share price to its earnings per share.
Total number of outstanding shares.
Gap between today's open and yesterday's close.
Average daily traded volume.
Highest price reached in the last 30 days.
Lowest price reached in the last 30 days.
Highest price reached in the last six months.
Lowest price reached in the last six months.
Highest price reached in the last year.
Lowest price reached in the last year.
Peer Comparison
| # | Name | Price | Chg % | P/E | EPS | Mkt Cap (Cr) | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|
| 1 | Shilpa Medicare Limited | 811.50 | +0.27% | 53.10 | 15.28 | 15,846 | 825.40 | 259.50 |
| 2 | Aarti Drugs Limited | 413.00 | +0.55% | 19.73 | 20.93 | 3,769 | 534.55 | 318.95 |
| 3 | Aarti Pharmalabs Limited | 874.50 | +1.46% | 37.21 | 23.50 | 7,930 | 946.10 | 585.00 |
| 4 | Abbott India Limited | 26,520.00 | -1.43% | 34.90 | 759.88 | 56,460 | 33,495.00 | 25,150.00 |
| 5 | ANLON HEALTHCARE LIMITED | 14.53 | +0.14% | 21.33 | 0.68 | 774 | 17.27 | 9.08 |
| 6 | Ajanta Pharma Limited | 3,710.00 | -0.22% | 40.84 | 90.83 | 46,255 | 3,796.00 | 2,329.90 |
| 7 | AKUMS DRUGS AND PHARMA L | 745.25 | +0.17% | 39.12 | 19.05 | 11,413 | 775.00 | 409.30 |
| 8 | Alivus Life Sciences Limited | 1,400.00 | +0.40% | 28.55 | 49.03 | 17,188 | 1,418.00 | 819.00 |
| 9 | Alkem Laboratories Limited | 5,475.00 | +1.88% | 30.34 | 180.45 | 65,462 | 5,933.50 | 5,075.00 |
| 10 | Amrutanjan Health Care Limited | 488.50 | -0.68% | 26.16 | 18.67 | 1,418 | 790.95 | 482.80 |
| 11 | Alembic Pharmaceuticals Limited | 826.50 | +0.49% | 23.44 | 35.27 | 16,246 | 1,002.00 | 635.80 |
| 12 | AstraZeneca Pharma India Limited | 7,621.00 | -0.26% | 112.32 | 67.85 | 19,053 | 9,849.50 | 7,551.50 |
| 13 | Aurobindo Pharma Limited | 1,636.20 | +0.55% | 25.56 | 64.00 | 95,154 | 1,682.40 | 1,016.10 |
| Median: 13 Co. | 874.50 | 0.27% | 30.34 | 35.27 | 16,246 | 1,002.00 | 635.80 |